Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:BIP
NYSE:BIPIntegrated Utilities

Brookfield Infrastructure Partners (NYSE:BIP) Margin Rebound Tests High P/E Bullish Narratives

Brookfield Infrastructure Partners' FY 2025 Earnings Snapshot Brookfield Infrastructure Partners (NYSE:BIP) closed out FY 2025 with fourth quarter revenue of about US$6.3 billion, basic EPS of US$0.40 and net income of US$245 million, putting a spotlight on how its profitability is tracking against expectations. The company has seen revenue move from US$5.4 billion in Q4 2024 to roughly US$6.3 billion in Q4 2025, while basic EPS shifted from US$0.26 to US$0.40 over the same period. This gives...
OM:BETS B
OM:BETS BHospitality

Will Softer Q4 Guidance and Ongoing Buybacks Change Betsson's (OM:BETS B) Investment Narrative?

In January 2026, Betsson AB (publ) issued preliminary guidance indicating that fourth-quarter 2025 revenue is expected to be about €304 million, with operating income (EBIT) around €53 million, both lower than the prior-year quarter. Alongside this softer earnings outlook, Betsson has continued repurchasing its own shares, which reduces the free float and can lift earnings per share for remaining shareholders. Against this backdrop of lower EBIT guidance but ongoing share buybacks, we will...
NYSE:CNMD
NYSE:CNMDMedical Equipment

One Off US$88 Million Loss And Margin Compression Test CONMED (CNMD) Bullish Narratives

CONMED (CNMD) just wrapped up FY 2025 with Q4 revenue of US$373.2 million and basic EPS of US$0.54, alongside trailing twelve month revenue of about US$1.4 billion and EPS of US$1.52. Over the past six quarters in the dataset, revenue has ranged from US$316.7 million to US$373.2 million per quarter, while quarterly EPS has moved between US$0.09 and US$1.59. With trailing net margin sitting at 3.4% versus 10.1% a year earlier, this latest result puts a clear focus on how sustainable the...
TSE:6367
TSE:6367Building

Daikin Targets Data Centers And Large Venues With New Cooling Systems

Daikin Industries (TSE:6367) has introduced new HVAC technologies aimed at hyperscale data centers and AI-driven workloads, scheduled to feature at the 2026 AHR Expo. The company has also announced the Multijet air conditioner, designed to provide highly targeted airflow for large venues and other large scale cooling needs. These product launches focus on energy efficiency and tailored cooling performance for commercial and mission critical environments. Daikin Industries, known for its air...
NYSE:VRT
NYSE:VRTElectrical

A Look At Vertiv (VRT) Valuation As AI Data Center Growth And Vertiv Next Predict Support Optimism

Vertiv Holdings Co (VRT) has been in focus after launching Vertiv Next Predict, an AI-powered managed service for data centers that uses predictive analytics to spot equipment risks early and streamline maintenance. See our latest analysis for Vertiv Holdings Co. The Vertiv Next Predict launch comes as momentum builds in the shares, with a 7.7% 7 day share price return, an 18.7% 30 day share price return and a 70.5% 1 year total shareholder return pointing to strong recent interest in the AI...
OM:SWED A
OM:SWED ABanks

Swedbank’s Big 2025 Dividend Despite Lower Earnings Might Change The Case For Investing In Swedbank (OM:SWED A)

Swedbank AB (publ) has reported that full-year 2025 net income fell to SEK 32,759 million from SEK 34,866 million, while proposing a total dividend of SEK 29.80 per share, including a SEK 9.35 special dividend, and confirming the immediate departure of long-serving board member Hans Eckerström. An interesting aspect is that Swedbank’s proposed total dividend of roughly SEK 33.50 billions represents a high payout ratio of 70% of 2025 profit, even as earnings per share eased. We will now...
NYSE:HCC
NYSE:HCCMetals and Mining

Warrior Met Coal (HCC) Is Down 6.3% After Blue Creek Ramp-Up Plans Draw Fresh Analyst Optimism

Earlier this week, UBS upgraded Warrior Met Coal to a Buy rating and highlighted the ramp-up of its Blue Creek metallurgical coal project, while Moody’s shifted its outlook on the company to positive. Together, the broker upgrade, credit outlook revision, and expectations for a tight metallurgical coal market have sharpened investor focus on Warrior Met Coal’s growth plans and execution risk at Blue Creek. Next, we will examine how the Blue Creek project’s expected production ramp-up could...
NYSE:RCL
NYSE:RCLHospitality

Royal Caribbean Cruises (RCL) Margin Jump Reinforces Bullish Profitability Narratives

Royal Caribbean Cruises (RCL) has just posted its FY 2025 numbers, with fourth quarter revenue at US$4.3b and basic EPS of US$2.78, capping a trailing twelve month run of US$17.9b in revenue and US$15.75 in EPS. Over recent periods the company has seen quarterly revenue move from US$3.8b and EPS of US$2.05 in Q4 2024 to US$5.1b and EPS of US$5.79 in Q3 2025, before this latest quarter. This sets up the full year against a backdrop of faster earnings growth than revenue and meaningfully higher...
NasdaqGS:UMBF
NasdaqGS:UMBFBanks

UMB Financial Q4 Beat Highlights Integration Progress And Valuation Gap

UMB Financial (NasdaqGS:UMBF) reported strong Q4 results, with earnings that exceeded prior expectations. The company highlighted record quarterly earnings supported by commercial loan activity and disciplined cost management. Management reported successful progress on integrating Heartland Financial, calling it a key milestone for the combined bank. UMB Financial, the parent of UMB Bank, operates across commercial banking, institutional banking, and asset servicing, so Q4 results provide a...
TSX:PAAS
TSX:PAASMetals and Mining

The Bull Case For Pan American Silver (TSX:PAAS) Could Change Following New 2026 Production Guidance - Learn Why

Pan American Silver recently reported unaudited 2025 production of 22.84 million ounces of silver and 742.2 thousand ounces of gold, and issued 2026 guidance targeting 25.0–27.0 million silver ounces and 700,000–750,000 gold ounces of attributable output. Against a backdrop of stronger precious metal prices and record free cash flow in the prior quarter, this combination of solid reported production and forward guidance has helped reinforce the company’s position within a sector currently...
WBAG:OMV
WBAG:OMVOil and Gas

OMV (WBAG:OMV) Valuation Check After Downgrade Impairments And Green Hydrogen Funding News

OMV (WBAG:OMV) is back in focus after a downgrade from RBC Capital Markets, sizeable non-cash impairments, and fresh funding for a large green hydrogen project, all ahead of full-year 2025 results. See our latest analysis for OMV. Despite the recent downgrade and Q4 impairment news, OMV’s 1-month share price return of 5.43% and 1-year total shareholder return of 41.34% suggest positive momentum that has been building rather than fading. If this mix of energy transition projects and market...
KOSE:A005930
KOSE:A005930Tech

Samsung Blends Olympic Phone Launch, Privacy Push And Buyback For Growth

Samsung Electronics launched the Galaxy Z Flip7 Olympic Edition for Milano Cortina 2026 Winter Games athletes, featuring AI tools, translation support, and digital pass integration. The company introduced a new tailored privacy feature for Galaxy devices, adding a customizable layer of protection across hardware and software. Samsung announced approval of a major share buyback plan, indicating its current capital allocation priorities and focus on shareholder returns. For investors watching...
NYSE:AROC
NYSE:AROCEnergy Services

Archrock Dividend Raise Highlights Confidence In Contract Backed Cash Flows

Archrock (NYSE:AROC) has announced an increase in its quarterly dividend. The higher payout was approved by the company's Board of Directors. Archrock, a natural gas compression services provider, sits at the heart of U.S. energy infrastructure, supporting the movement of gas from production fields to end users. For income focused investors, a dividend change at a company tied to midstream energy activity can be a meaningful signal about how management views the business and its capital...
NasdaqGM:KYMR
NasdaqGM:KYMRBiotechs

Assessing Kymera Therapeutics (KYMR) Valuation After Strong 3 Month And 1 Year Share Price Gains

Kymera Therapeutics (KYMR) has drawn attention recently, with the stock up about 19.5% over the past 3 months and about 82.7% over the past year. This performance is prompting investors to reassess its profile. See our latest analysis for Kymera Therapeutics. That recent 3.86% 1 day share price return, together with a 19.5% 90 day share price return and 82.7% 1 year total shareholder return, points to momentum building around Kymera as investors reassess its risk and growth profile following...
ENXTAM:ARCAD
ENXTAM:ARCADProfessional Services

How Arcadis’ Role in Dutch Nuclear New Build Planning At Arcadis (ENXTAM:ARCAD) Has Changed Its Investment Story

Amentum announced that its NEXUS-NL consortium, including Arcadis, Tractebel and NRG PALLAS, previously secured a framework contract worth up to €180 million to support planning and development of up to two new gigawatt-scale nuclear power plants in the Netherlands. This win places Arcadis at the center of a high-profile nuclear new build program, handling siting studies and complex licensing and permitting work for the Dutch government’s decarbonization agenda. We’ll now examine how...
NasdaqCM:RGC
NasdaqCM:RGCPharmaceuticals

A Look At Regencell Bioscience Holdings (RGC) Valuation After Market Value Surges Despite Ongoing Challenges

Regencell Bioscience Holdings (RGC) is back in focus after recent coverage highlighted a sharp surge in its market value, despite having no revenue, recurring losses, and an ongoing Justice Department investigation. See our latest analysis for Regencell Bioscience Holdings. The share price has been volatile, with a 1 day share price return of a 13.61% decline and a 7 day share price return of a 9.34% decline. Despite this, it still sits on a 30 day share price return of 21.81% and a 90 day...
NYSE:VFC
NYSE:VFCLuxury

VF Corp (VFC) Q3 Profit Rebound Tests Valuation Concerns In Bullish Narratives

V.F. Corporation (VFC) just posted Q3 2026 results with revenue of US$2.9b and basic EPS of US$0.77, setting a clear reference point for how the year is shaping up. The company has seen quarterly revenue move from US$2.8b in Q2 2026 and US$2.9b in Q3 2025, while EPS shifted from US$0.49 in Q2 2026 and US$0.43 in Q3 2025, giving investors a clean view of how the income statement is trending as margins settle after a volatile period. See our full analysis for V.F. With the latest numbers on the...
NasdaqGS:AMGN
NasdaqGS:AMGNBiotechs

Sagebrush Lawsuit Tests Amgen 340B Practices And Investor Risk Views

Sagebrush Health Services has filed a lawsuit accusing Amgen (NasdaqGS:AMGN) of unlawfully terminating discounted drug sales under the federal 340B Drug Pricing Program. The complaint alleges Amgen improperly retracted discounts and reclaimed millions in price concessions that supported clinics serving underserved patients. The dispute centers on access to Amgen therapies for vulnerable populations and the company’s handling of federal discount requirements. Amgen, a large biotechnology...
NasdaqGS:KLAC
NasdaqGS:KLACSemiconductor

KLA Upgrades Highlight 2nm Inspection Demand And Recent Earnings Strength

Multiple major analysts upgraded KLA (NasdaqGS:KLAC), citing strong demand for advanced semiconductor inspection equipment and growth in 2nm process technology. KLA reported significantly improved quarterly financial results, with revenue and profit both moving higher. The combination of analyst upgrades and the latest earnings release has sharpened investor focus on KLA's role in next generation chip manufacturing. KLA enters this news cycle with its share price at $1,684.71 and a very...
NYSE:PFE
NYSE:PFEPharmaceuticals

Pfizer (PFE) Valuation Check After Novavax Licensing Deal And New Oncology Breakthrough Therapy Designation

Pfizer (PFE) is back in focus after two fresh pipeline updates: a non-exclusive Matrix M vaccine adjuvant licensing deal with Novavax and FDA Breakthrough Therapy Designation for a gastrointestinal stromal tumor combination. See our latest analysis for Pfizer. These pipeline headlines arrive while the share price has been edging higher, with a 30 day share price return of 4.44% and a 90 day share price return of 5.88%. However, the 3 year total shareholder return decline of 29.45% shows how...
TSX:CCO
TSX:CCOOil and Gas

Cameco Westinghouse Deal Links U.S. Nuclear Buildout To Rich Valuation

Cameco's Westinghouse segment has signed an agreement with the U.S. Department of Commerce to support significant new nuclear reactor construction in the U.S. The deal is described as a landmark arrangement, with the potential to materially affect Cameco's earnings profile through expanded U.S. nuclear activity. The agreement connects TSX:CCO more closely with U.S. nuclear policy and global shifts in uranium sourcing away from Russian supply. For investors watching TSX:CCO, this move ties...
NasdaqGS:INTU
NasdaqGS:INTUSoftware

Intuit (INTU) Valuation Check As Career Pipeline Program And QuickBooks Checkr Integration Draw Fresh Attention

Intuit (INTU) is drawing fresh attention as the U.S. tax season opens, with investors weighing its new Career Pipeline Program, the QuickBooks partnership with Checkr, and recent stock price weakness together. See our latest analysis for Intuit. Those new product and partnership moves are landing at a tricky moment for the stock, with a 1 day share price return of 6.63% decline at US$502.98, a 30 day share price return of 24.91% decline, and a 1 year total shareholder return of 16.24%...
NasdaqGS:CSGP
NasdaqGS:CSGPReal Estate

Third Point Escalates CoStar Battle Over Board And Residential Focus

Third Point has escalated its activist campaign at CoStar Group, pushing for a board overhaul and fresh directors at NasdaqGS:CSGP. The fund is urging CoStar to refocus on its core commercial real estate data business and consider divesting its residential real estate operations. Third Point has publicly criticized governance, strategy, and management compensation, framing its campaign as an effort to restore shareholder value. For shareholders, this fight comes after a challenging run for...